1-tert-butyl-3-methyl 2-(2-(isopropylthio)-5-nitrophenyl)pyrrolidine-1,3-dicarboxylate | 900174-39-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-tert-butyl-3-methyl 2-(2-(isopropylthio)-5-nitrophenyl)pyrrolidine-1,3-dicarboxylate
• 英文别名: 1-O-tert-butyl 3-O-methyl 2-(5-nitro-2-propan-2-ylsulfanylphenyl)pyrrolidine-1,3-dicarboxylate
• CAS: 900174-39-2
• 化学式: C₂₀H₂₈N₂O₆S
• 分子量: 424.518
• InChiKey: IHZVEBJQFCJXOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  127
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-tert-butyl-3-methyl 2-(2-(isopropylthio)-5-nitrophenyl)pyrrolidine-1,3-dicarboxylate 在 palladium 10% on activated carbon 、 氢气 、 碳酸氢钠 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 1-tert-butyl 3-methyl (2R,3S)-2-(5-amino-2-(isopropylsulfonyl)phenyl)pyrrolidine-1,3-dicarboxylate
  参考文献：
  名称：

  Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors

  摘要：

  Inhibitors of the Tissue Factor/Factor VIIa (TF-FVIIa) complex are promising novel anticoagulants that show excellent efficacy and minimal bleeding in preclinical models. On the basis of a zwitterionic phenylglycine acylsulfonamide 1, a phenylglycine benzylamide 2 was shown to possess improved permeability and oral bioavailability. Optimization of the benzylamide, guided by X-ray crystallography, led to a potent TF-FVIIa inhibitor 18i with promising oral bioavailability, but promiscuous activity in an in vitro safety panel of receptors and enzymes. Introducing an acid on the pyrrolidine ring, guided by molecular modeling, resulted in highly potent, selective, and efficacious TF-FVIIa inhibitors with clean in vitro safety profile. The pyrrolidine acid 20 showed a moderate clearance, low volume of distribution, and a short t(1/2) in dog PK studies.

  DOI：

  10.1021/ml400453z

文献信息

• Phenylglycinamide derivatives useful as anticoagulants
  申请人：Zhang Xiaojun

  公开号：US20060166997A1

  公开（公告）日：2006-07-27

  The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

  本发明一般涉及抑制丝氨酸蛋白酶的苯基甘氨酰衍生物。具体而言，本发明涉及新型苯基甘氨酰衍生物及其类似物，其可用作凝血级联反应的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶、第VIIa因子、第Xa因子、第XIa因子、第IXa因子和/或血浆激肽。特别是，它涉及到的化合物是第VIIa因子的抑制剂。本发明还涉及包含这些化合物的制药组合物及其使用方法。
• WO2006/76246
  申请人：——

  公开号：——

  公开（公告）日：——
• WO2008/79759
  申请人：——

  公开号：——

  公开（公告）日：——
• PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1856096B1

  公开（公告）日：2010-09-01
• US7622585B2
  申请人：——

  公开号：US7622585B2

  公开（公告）日：2009-11-24